FGF23 and stage 5 chronic kidney disease: Although its value as a clinical biomarker remains under discussion, some studies showed that FGF23 is an independent predictor of adverse outcomes in CKD patients, observing an association between high FGF23 levels with increased cardiovascular risk and progression to end-stage renal disease requiring renal replacement therapy (RRT) [126,127,128,129].